Previously reported Phase 1/2 data on WU-CART-007 demonstrated clinically manageable safety and evidence of anti-leukemic activity with an overall response rate of 91% and composite complete remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback